NCT00768144 2018-08-24
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
3 trialsNCT00388037 2015-01-27
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00543049 2014-03-07
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
AGO Study Group
Phase 2 Completed